IVPR · Inspire Veterinary Partners, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred recurring losses and as of September 30, 2025, had an accumulated deficit and negative working capital of $44,326,159 and 5,894,301, respectively. For the three and nine months ended September 30, 2025, the Company sustained a net loss of $2,526,273 and $7,975,878, respectively. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the date these financial statements were issued.”View the 10-Q filed Nov 12, 2025
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-05-28 | Kees Lynley |
Chief People Officer |
Award↑
|
Stock Option (right to buy)
|
34,247 |
| 2025-05-16 | Carr Kimball |
Director, See Remarks |
Award↑
|
Stock Option (right to buy)
|
92,593 |
| 2025-04-01 | Frank Richard |
Chief Financial Officer |
Award↑
|
Stock Option (right to buy)
|
58,480 |
| 2024-12-26 | Watters Timothy |
Director |
Sell↓
|
Class A Common Stock
|
467 |
| 2024-09-26 | Thomas-Mackey Erinn |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On January 27, 2025, the issuer effected a 25 to 1 reverse stock split of its Class A Common Stock. The number of shares of Class A Common Stock reported on this Form 4 has been adjusted to reflect the reverse stock split. |
Stock Option (right to buy)
|
1,447 |
| 2024-09-26 | Murphy Anne |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On January 27, 2025, the issuer effected a 25 to 1 reverse stock split of its Class A Common Stock. The number of shares of Class A Common Stock reported on this Form 4 has been adjusted to reflect the reverse stock split. |
Stock Option (right to buy)
|
1,447 |
| 2024-09-26 | Lawrence Alexander |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On January 27, 2025, the issuer effected a 25 to 1 reverse stock split of its Class A Common Stock. The number of shares of Class A Common Stock reported on this Form 4 has been adjusted to reflect the reverse stock split. |
Stock Option (right to buy)
|
1,447 |
| 2024-09-26 | Keiser Charles Stith |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On January 27, 2025, the issuer effected a 25 to 1 reverse stock split of its Class A Common Stock. The number of shares of Class A Common Stock reported on this Form 4 has been adjusted to reflect the reverse stock split. |
Stock Option (right to buy)
|
953 |
| 2024-09-26 | Watters Timothy |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On January 27, 2025, the issuer effected a 25 to 1 reverse stock split of its Class A Common Stock. The number of shares of Class A Common Stock reported on this Form 4 has been adjusted to reflect the reverse stock split. |
Stock Option (right to buy)
|
1,447 |
| 2024-07-10 | Alomari Ahmed |
10% Owner |
Sell↓
|
Class A Common Stock
|
50,000 |
| 2023-11-20 | Lawrence Alexander |
Director |
Buy↑
|
Class A Common Stock
|
1,000 |
| 2023-11-17 | Keiser Charles Stith |
Director |
Buy↑
|
Class A Common Stock
|
1,800 |
| 2023-11-16 | Thomas-Mackey Erinn |
Director |
Buy↑
|
Class A Common Stock
|
5,600 |
| 2023-11-15 | Carr Kimball |
Director, See Remarks |
Buy↑
Filing footnotes — Class A Common Stock (Direct)
Includes and constitutes a Warrant to purchase 50,000 shares of Class A common stock issued to Mr. Carr in connection with his personal guaranty of certain loans to the issuer. The Warrant is exercisable from time to time and at any time, in whole or in part, by the holder thereof on a cash- or cashless-exercise basis. |
Class A Common Stock
|
5,000 |